Hoffmann-la Roche Inc.

Roche Glycart Ag

F. Hoffmann-la Roche Ag

Wilma Lau

Erhard Kopetzki

Ulrich Brinkmann

Guy Georges

Adelbert Grossmann

Christian Schantz

Friederike Hesse

Rebecca Croasdale

Christian Klein

Pablo Umana

Joerg Thomas Regula

Olaf Mundigl

Werner Scheuer

Juergen Michael Schanzer

Eike Hoffmann

Harald Duerr

Alexander Haas

Johannes Auer

Jan Olaf Stracke

Katharina Wartha

Silke Metz

Rebecca Croasdale-Wood

The invention provides anti-BRDU antibodies and methods of using the same.

Anti-BRDU antibodies and methods of use

The present invention relates to bispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Bispecific antibodies

The present invention relates to complexes of a) bi-specific antibodies and antibody fragments against a target protein and b) a digoxigenin conjugated to a therapeutic or diagnostic agent, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical compositions containing said antibodies, and uses thereof.

Complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent

Herein is reported a method for the recombinant production of a polypeptide, which comprises the dipeptide AR, characterized in that the method comprises the recovering of the polypeptide from the cells or the cultivation medium of a cultivation of a cell comprising a nucleic acid encoding the polypeptide and thereby producing the polypeptide, whereby the dipeptide AR comprised in the polypeptide is encoded by the oligonucleotide gca cgt, or the oligonucleotide gcg cgt, or the oligonucleotide gcc cgt.

Method for reduction of 1-&#x3e;2 reading frame shifts

A pro-polypeptide which is useful for the expression of a polypeptide of interest in a prokaryotic cell. Therefore the pro-polypeptide is fused to the N-terminus of the polypeptide of interest. The pro-polypeptide as reported herein provides for improved expression yields and improves the handling of the fusion polypeptide (downstream processing, purification). For example, efficient endotoxin removal is effected while the protein of interest comprising the pro-polypeptide is bound e.g. to an affinity chromatography material. Thereafter the pro-polypeptide can efficiently be cleaved from the polypeptide of interest by the incorporated protease cleavage site with the cognate protease.

Prokaryotic expression construct

Growing community of inventors

Munich, Germany

Wilma Lau